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ABSTRACT
Objective: To estimate the long-term cost-effectiveness of adding piogli-
tazone versus placebo to standard treatment in high-risk patients with type
2 diabetes.
Methods: The validated CORE Diabetes Model was modiﬁed to project
long-term clinical and cost outcomes associated with pioglitazone versus
placebo, based on results from PROactive. The model retained basic
structure and functionality, with interdependent Markov submodels,
Monte Carlo simulation and user interface. Adjustments to submodels
were made to accommodate the PROactive primary end points. The
analysis was from the perspective of a third party US health-care payer
perspective, projected over a lifetime horizon using a 3% annual
discount.
Results: Over a lifetime horizon, addition of pioglitazone was associated
with increased life expectancy (0.237 life-years) and quality-adjusted life
expectancy (QALE) [0.166 quality-adjusted life-years (QALYs)] versus
placebo. Estimated long-term complication rates showed that pioglitazone
reduced the number of events versus placebo for most outcomes. Lifetime
total direct costs were marginally higher with pioglitazone versus placebo
($272,694 vs. $265,390, difference $7,305). The incremental cost-
effectiveness ratio for pioglitazone versus placebo was $44,105 per QALY
gained. Probabilistic sensitivity analysis indicated a 55% likelihood that
pioglitazone would be considered cost-effective in the United States, with
a willingness to pay of $50,000 per QALY gained.
Conclusions: The addition of pioglitazone to existing therapy in high-risk
patients with type 2 diabetes was projected to improve life expectancy,
QALE and complication rates compared with placebo. Addition of piogli-
tazone was in the range generally considered acceptable.
Keywords: costs, modeling, outcomes, pioglitazone, type 2 diabetes.
Introduction
The global prevalence of type 2 diabetes is approximately 200
million and is expected to increase to nearly 300 million by 2025
[1]. The disease is associated with an enormous health-care
burden, accounting for approximately 10% of global health-care
expenditure [2]. Macrovascular complications, including coro-
nary artery disease, myocardial infarction, and stroke, account
for almost 80% of all diabetes-related mortality, contributing to
an average reduction in life expectancy of approximately 10
years for diabetes patients versus the general population [3].
One of the main aims of treating type 2 diabetes is to prevent
or delay the onset of micro- and macrovascular complications. It
is well established that improving patients’ glycemic control (in
terms of glycosylated hemoglobin), as well as cardiovascular risk
factors (blood pressure, serum lipid levels, etc.), can substan-
tially reduce the risk of diabetes-related complications [4–8].
Pioglitazone is a member of the thiazolidinediones class of oral
antidiabetic agents and has been demonstrated to have blood
glucose-lowering properties, as well as beneﬁcial effects on trig-
lyceride and high-density lipoprotein levels [9–11]. The PRO-
spective pioglitAzone Clinical Trial In macrovascular Events
(PROactive) was the ﬁrst large-scale cardiovascular outcomes
study to investigate prospectively the effect of an oral hypogly-
cemic agent on macrovascular outcomes [12].
PROactive was a prospective, international, multicenter,
double-blind, randomized, parallel group study that enrolled
5238 patients with type 2 diabetes and established macrovascu-
lar disease deﬁned as one or more of the following: more than
6-month history of myocardial infarction (MI), coronary artery
revascularization, stroke; 3-month history of acute coronary syn-
drome (ACS), other evidence of coronary artery disease or
peripheral arterial obstructive disease. The study’s design and
results have been described in detail elsewhere [13,14]. Brieﬂy,
pioglitazone or placebo was administered on top of existing
diabetes treatments, including exercise and diet and other
glucose-lowering therapies with or without insulin, and titrated
up to 45 mg daily as tolerated. Additionally, patients were
treated as necessary with cardiovascular medications, including
lipid-lowering therapies and antihypertensives. Throughout the
study, diabetes and cardiovascular therapies were adjusted as
necessary according to the International Diabetes Federation
(Europe) guidelines [15]. At baseline, 10% and 20% of patients
were receiving metformin (MET) and sulfonylurea (SU) mono-
therapy, respectively; 25% were receiving MET + SU combina-
tion therapy, and 34% were receiving insulin. Pioglitazone was
administered to 2605 patients and placebo to 2633 patients. The
study population had a mean age of 61.8 years and an average
duration of diabetes of 6 years. Over 80% of patients within each
cohort completed the study while on study medication (Fig. 1),
and the mean exposure to study drug was 30.4 months.
After 36 months of follow-up (average follow-up, 34.5
months), there was a nonsigniﬁcant 10% relative risk reduction
with pioglitazone in the primary end point (P = 0.095), which
was a composite of all-cause mortality, nonfatal myocardial inf-
arction (including silent myocardial infarction), stroke, acute
coronary syndrome, endovascular or surgical intervention in the
coronary or leg arteries, and amputation above the ankle. Piogli-
tazone was, however, associated with a signiﬁcant relative risk
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reduction of 16% (P = 0.027) in the main secondary end point of
all-cause mortality, myocardial infarction (excluding silent myo-
cardial infarction), and stroke. Additionally, pioglitazone treat-
ment was associated with signiﬁcant decreases in triglyceride
levels (-11.4% vs. 1.8% with placebo; P < 0.0001) and increases
in high-density lipoprotein cholesterol (HDL-C) levels (19.0%
vs. 10.1% with placebo; P < 0.0001). Despite a signiﬁcantly
greater increase in low-density lipoprotein cholesterol (LDL-C)
observed with pioglitazone (7.2% vs. 4.9% with placebo;
P < 0.003), there was signiﬁcant reduction in the LDL-C to
HDL-C ratio with pioglitazone compared with placebo (-9.5 vs.
-4.2: P < 0.0001). Pioglitazone also reduced the number of
patients progressing to long-term insulin therapy by half com-
pared with placebo (P < 0.0001). The observed increased risk of
any reported heart failure (11% vs. 8% with placebo;
P < 0.0001) with (6% vs. 4% with placebo; P < 0.007) and
without hospitalization (5% vs. 3% with placebo; P < 0.003)
were also included in our analyses.
We developed a working hypothesis that the clinical beneﬁts
observed with pioglitazone in PROactive could lead to economic
beneﬁts in terms of reduced complication costs and insulin treat-
ment costs. These cost reductions could, at least in part, offset the
additional costs of pioglitazone treatment. To test our hypoth-
esis, we adapted the CORE Diabetes model, a validated, pub-
lished, Internet-based model of type 2 diabetes, to the PROactive
clinical end point data and projected diabetes-related complica-
tions and associated direct medical costs by treatment over the
lifetime horizon in the US setting.
Methods
The CORE Diabetes model (CDM) was used to estimate the
health and economic impact of pioglitazone treatment versus
placebo over the lifetime horizon based on short-term clinical
data (0–3 years) from PROactive [16,17]. The model was used to
project life expectancy, quality-adjusted life expectancy [based on
quality of life data from the Cost of Diabetes in Europe—Type II
study (CODE-2)] [18], cumulative incidence of diabetes-related
complications and direct medical costs, and to calculate
cost-effectiveness.
Model Description
A brief overview of the CORE Diabetes model is provided here,
but the interested reader is referred elsewhere for additional
detail [16,17]. The CDM is an interactive, Internet-based com-
puter simulation model developed to estimate the long-term
health outcomes and economic consequences of type 1 and type
2 diabetes interventions. The model is nonproduct-speciﬁc and
designed to support diabetes policy decision-making. It performs
real-time simulations, taking into account various insulin therapy
regimens, oral antidiabetic agents, and screening and treatment
strategies for microvascular complications. Diabetes progression
is based on a series of interdependent Markov submodels that
simulate the micro-and macrovascular, and acute metabolic com-
plications of diabetes. Each submodel uses diabetes type-
dependent health state transition probabilities derived from
published sources and can interact with other complication sub-
models. Traditional Markov mathematical models do not possess
virtual memory. One of the shortcomings of a standard Markov
model is that there is no memory (i.e. the model cannot record
when a patient experiences an event in the simulation). This is
overcome using tracker variables in the sub-models of the CORE
Diabetes Model. Tracker variables act as ﬂags in the model,
which are raised when a patient experiences events or complica-
tions during the simulation, and this in turn can be used to
Cost per patient ($)
Total complication costs
ACS
PCI
CABG
Bypass surgery / leg revasc.
Hosp. for heart failure
Nonserious heart failure
Edema
Myocardial infarction
TIA
Stroke
Cardiovascular-related mortality
Photocoagulation / SVL
Nephropathy
Neuropathy
PVD
Foot ulcer
Major leg amputation
Cataract
Hypoglycemia
-1,000-7,000 0-4,000 -2,000-3,000 1,000 2,000-6,000 -5,000
Figure 1 Summary of complication costs over patient lifetimes. ACS, acute coronary syndrome;CABG, coronary artery bypass grafting; PCI, percutaneous coronary
intervention; PVD, peripheral vascular disease; SVL, severe vision loss;TIA, transient ischemic attack.
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inﬂuence the calculation of quality-adjusted life expectancy, costs
and to adjust the risk of subsequent events in the simulation
(including across different sub-models). For example, a tracker
variable is used record the onset of angina in a simulated patient.
This is recorded in the database and the risk of subsequent events
for that patient, for instance myocardial infarction or stroke, is
adjusted appropriately. Patient cohorts are deﬁned in terms of
diabetes type, demographics, baseline risk factors, and pre-
existing complications. Economic and clinical data can be edited
by the user, enabling new data to be incorporated as they become
available. Diabetes management strategies geared toward
improving the quality of care for diabetes patients can be com-
pared in a variety of clinical settings. The reliability of simulated
outcomes has been tested, with results validated against those
reported by clinical trials and epidemiological studies [17].
Modiﬁcations to the CORE Diabetes Model
for PROactive
A description of the changes made to the CDM to incorporate
data from the PROactive study has been previously published
[19]. To incorporate clinical end point data from PROactive into
the CORE Diabetes model, a number of new health state sub-
models were developed to include the following events: acute
coronary syndrome, coronary artery bypass grafting and percu-
taneous coronary intervention, bypass surgery/revasculariza-
tion of the leg, above-ankle amputation, peripheral edema,
photocoagulation/severe vision loss, hospitalization following
heart failure, transient ischemic attack, cardiovascular-related
mortality, and all-cause mortality. Two of the existing submodels
were modiﬁed in line with the available clinical data from PRO-
active. These were the myocardial infarction (nonfatal myocar-
dial infarction) and stroke (nonfatal stroke) submodels. The
original version of the CDM had six submodels that were inac-
tivated, with most replaced with PROactive-speciﬁc submodels.
First, the angina submodel of the CDMwas replaced by the ACS,
coronary bypass graft (CABG) and percutaneous coronary inter-
vention (PCI) submodels, allowing additional details on risk
adjustment to be introduced. Second, the congestive heart failure
(CHF) submodel of the CDMwas replaced by the hospitalization
following heart failure submodel, which made the risk adjust-
ment more speciﬁc to PROactive and the thiazolidinedione
(TZD) class of oral antidiabetic drugs. Third, nonspeciﬁc mor-
tality in the CDM was replaced by the all-cause mortality and
cardiovascular mortality submodels in PROactive, which were
collected as part of the study. Fourth, the macular edema sub-
model of the CDM was broadened to include edema, as this was
a very important ﬁnding of the PROactive study. Lastly, the
ketoacidosis and lactic acidosis submodels of the CDM were
inactivated as they have not been observed to be outcomes rel-
evant to TZD treatment and were also not observed in PROac-
tive. Beyond the submodel additions and adjustments, the overall
architecture of the CORE Diabetes model was analogous to the
original version, with all submodels running in parallel to simu-
late the progression of disease and the development of diabetes-
related complications.
PROactive Event Rates
Event rates in the placebo arm were calculated directly from the
annual hazard rates observed over months 0–36 of PROactive
assuming constant risk. Constant risk, or the annual average for
each event, was assumed for application of hazard ratios to
calculate event rates in the pioglitazone arm for all end points
with the exception of edema, where hazard ratios were sampled
from separate distributions for the ﬁrst year and subsequent
years of the simulation. Hazard ratios were then applied to the
event rates from the placebo arm in line with the relative risk
observed for each event during PROactive to calculate event rates
in the pioglitazone treatment arm. To capture the statistical
uncertainty in the trial data, hazard ratios in the modeling simu-
lations were randomly sampled from a log-normal distribution
generated from mu and sigma values derived directly from the
trial data, which correspond to geometric means and standard
deviations. Constant risk was assumed for application of hazard
ratios to calculate event rates in the pioglitazone arm for all end
points with the exception of edema, where hazard ratios were
sampled from separate distributions for the ﬁrst year and subse-
quent years of the simulation.
During simulations, event rates in all years beyond the trial
period (i.e. years 4+) were calculated by applying a relative risk
adjustment for each additional life-year gained (i.e., as the
patient gets older, his/her risk of experiencing an event increases).
Each event was associated with a speciﬁc relative risk adjustment
based on published data as previously described [19].
In all complication submodels, the occurrence of events
resulted in the accrual of event costs, and, where applicable,
subsequent state costs as well as application of the appropriate
quality of life utility values.
Estimation of Mortality
All-cause and cardiovascular mortality rates were derived from
the PROactive Study for years 1–3 of the simulation, with rates
subsequently doubling every 10 years [20]. Event rates for all
subsequent years were calculated by applying relative risk adjust-
ments [21–24] for each additional life-year gained (i.e., as the
patient gets older, his/her risk of experiencing an event increases).
In all submodels, the occurrence of events resulted in the accrual
of event costs, and, where applicable, subsequent state costs as
well as an assignment of the appropriate disutility values.
Simulated Cohort
Two cohorts of patients were deﬁned with baseline demograph-
ics, baseline complications, and important concomitant medica-
tions representative of the two treatment arms from PROactive
(Table 1). The use of a combined cohort is common in health
economic analysis so that baseline risk factors do not act as a
confounder to the application of treatment effects during the
simulation [25]. Long-term outcomes were calculated in the
model using a simulated population of 1000 patients, with base-
line characteristics consisting of 66.1% male and a mean age of
61.8 years. At baseline, patients had a mean duration of diabetes
of 10 years, with a mean HbA1c level of 8.1%. For the purposes
of this analysis, patients were assumed to remain on the same
treatment regimen for the duration of the simulation (35 years or
death).
Intervention Effects
For the base-case simulation, the clinical effects associated with
the pioglitazone and placebo treatment regimens were applied as
observed from PROactive. Treatment effects on HbA1c were
applied separately in simulation years 1, 2, and 3 based on the
ﬁndings from PROactive, and, in subsequent years, followed the
United Kingdom Prospective Diabetes Study (UKPDS) long-term
pattern [4]. Changes in HbA1c and other parameters for piogli-
tazone and placebo regimen effects were applied as summarized
in Table 2. The long-term progression of all of these clinical
parameters subsequently followed the patterns previously
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described by Palmer et al. in their description of the CORE
Diabetes Model [16]. HbA1c levels were assumed to increase by
0.15% points in both treatment arms from year 4 until the end of
the simulation, in line with observations made in the UKPDS [4].
Costs
Direct medical costs over the lifetime horizon were accounted
from a third-party health-care payer perspective (Medicare) in
the United States. All costs were expressed in 2005 US dollars ($).
Costs retrieved from published sources that were not expressed
in 2005 values were inﬂated using the US Bureau of Labor
Statistics Consumer Price Index calculator [26]. Direct medical
costs comprised treatment, patient management, and complica-
tions costs.
In all submodels, the occurrence of events resulted in the
accrual of event costs, and, where applicable, subsequent state
costs. Treatment costs were calculated on an annual basis as the
sum of study medication costs, other antidiabetes medication
costs, and cardiovascular medication costs, based on the daily
resource use data from PROactive, for the ﬁrst 3 years. The daily
pharmacy costs for pioglitazone in the United States were $2.86,
$4.59, and $4.98 for 15 mg, 30 mg, and 45 mg doses, respec-
tively [27]. Cardiovascular medication costs are summarized in
Table 3. For all subsequent years in the simulation, the annual
treatment costs of year 3 were applied. Patient management costs
included the costs of screening for retinopathy and microalbu-
minuria, and the costs of lower extremity ulcer treatments. The
cost of complications accounted for events that occurred during
the simulation, and, for certain events, included the state or
follow-up costs, as projected by the model. The unit costs of
complications are summarized in Table 4.
Quality of Life Calculation
For the base case analysis, health state utilities for the events
reported in PROactive were derived, wherever possible, from the
CODE-2 disutility data [18]. Where PROactive events were not
taken into consideration in the CODE-2 formula, no substitute
values were used. All other quality of life utilities used in the
sensitivity analyses have been described previously by Palmer
et al. [16]. Univariate sensitivity analyses were performed to
investigate the impact of including alternative disutilities.
A function that enabled evaluation of the impact of insulin
treatment on quality of life was added to the CORE Diabetes
model for the purposes of this analysis. Recent studies have
suggested that insulin treatment reduces quality of life, and this
has been quantiﬁed by the CODE-2 [18] and the University of
Michigan [28]. The model assigned quality of life disutilities
associated with insulin use based on the proportion of patients in
the simulated cohort receiving insulin. This proportion of insulin
users could be set for each of the ﬁrst 5 years of the simulation,
with the year-5 value carried forward for subsequent years. In the
base case analysis, the disutility for insulin use was set to -0.049
as speciﬁed in CODE-2.
Patient Management
The proportion of patients receiving angiotensin converting
enzyme (ACE) inhibitors in the simulation cohort was set to
62.8% based on data from PROactive. Risk adjustment for the
use of aspirins or statins was disabled in the CORE Diabetes
model, as the inﬂuence of these agents was already taken into
account, along with the impact of ACE inhibitors, in the cardio-
vascular event rates taken from PROactive. Other settings for
patient management parameters (e.g., screening for renal and eye
Table 1 Summary of the baseline characteristics of the simulation
cohort
Characteristic Value Data source
Demographics
Proportion male (%) 66.1 PROactive
Mean age (years) 61.8 PROactive
Duration of diabetes (years) 10 PROactive
Ethnic group
Proportion white (%) 98.6 PROactive
Proportion black (%) 1.4 PROactive
Baseline risk factors
HbA1c (%-points) 8.1 PROactive
Systolic blood pressure (mmHg) 143.4 PROactive
Body mass index (kg/m2) 30.9 PROactive
HDL-C (mg/dl) 46.44 PROactive
LDL-C (mg/dl) 116.10 PROactive
Total cholesterol (mg/dl) 201.52 PROactive
Triglycerides (mg/dl) 194.92 PROactive
Proportion smokers (%) 13.8 PROactive
Baseline complications
Acute coronary syndrome(%) 13.65 PROactive
CABG/PCI (%) 30.75 PROactive
Peripheral vascular disease (%) 24.3 PROactive
Myocardial infarction (%) 47.0 PROactive
Stroke (%) 19.0 PROactive
Microalbuminuria (%) 14.3 PROactive
Neuropathy (%) 25.6 PROactive
CABG, coronary artery bypass graft surgery; HDL-C, high density lipoprotein cholesterol;
LDL-C, low density lipoprotein cholesterol; PCI, percutaneous coronary intervention.
Table 2 Summary of base-case intervention effects on HbA1c
Pioglitazone Placebo
Change in HbA1c in year 1 (%-points) -0.9 -0.3
Change in HbA1c in year 2 (%-points) +0.1 +0.1
Change in HbA1c in year 3 (%-points) +0.3 +0.2
Change in subsequent years +0.15 +0.15
Total cholesterol (mg/dl) +34.6 +21.96
HDL-C (mg/dl) +21.0 +11.9
LDL-C (mg/dl) +13.6 +8.7
Triglycerides (mg/dl) -5.7 +6.8
Systolic blood pressure (mmHg) -3.8 -2.4
Body mass index (kg/m2) +1.1 -0.1
Hypoglycemic event rate (per 100 patient years) +9.29 +6.68
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.
Table 3 Cardiovascular medication costs per day
Medication Daily cost of medication ($)
Beta-blockers 8.712
ACE inhibitors 0.921
Calcium channel blockers 1.294
Nitrates 0.412
Angiotensin II antagonists 0.024
Alpha blockers 0.024
Thiazide diuretics 0.024
Loop diuretics 0.931
Potassium sparing diuretics 1.773
Cardiac glycosides 0.123
Antiarrhythmics 0.291
Acetylsalicylic acid 0.160
Ticlopinide/clopidogrel 3.530
Oral anticoagulants 0.402
Statins 3.722
Fibrates 3.624
Source: Grover et al. [27].
ACE, angiotensin converting enzyme.
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disease and foot ulcer prevention programs) were applied as
previously described by Palmer et al. [16].
Time Horizon and Discounting
A lifetime horizon of 35 years was used in the analysis to capture
all relevant long-term complications, their associated costs, and
impact on life expectancy. Future costs and clinical beneﬁts were
discounted at 3.0% per annum in line with recent recommenda-
tions for analyses in the US setting [29].
Statistical Approach
The cost-effectiveness analysis was performed using a nonpara-
metric bootstrapping approach in which the progression of dia-
betes was simulated in 1000 patients run through the model
1000 times to calculate the mean and standard deviation of costs,
life expectancy, and quality-adjusted life expectancy using second
order Monte Carlo simulation [30]. Mean results of each of the
1000 iterations were used to create a scatterplot that compared
the differences in outcomes for the pioglitazone and placebo
treatment regimens. These values were in turn used to generate
an acceptability curve over a range of willingness to pay values in
the US setting.
Sensitivity Analysis
Univariate sensitivity analyses were performed to investigate the
robustness of the base case ﬁndings. To investigate the inﬂuence of
time horizon on the ﬁndings, sensitivity analyses were performed
with the time horizon set to 5, 10, and 20 years. The effect of the
improvement in HbA1c associated with pioglitazone treatment
was investigated with a sensitivity analysis in which the change
from baseline in HbA1c reported in the placebo arm was applied
to both treatment arms. A sensitivity analysis was performed
where no risk adjustments for age were applied during the simu-
lation (risk adjustment factors all set to equal one). To investigate
the assumption that the effects associated with pioglitazone treat-
ment were transient, a sensitivity analysis was performedwhereby
the clinical beneﬁts associated with pioglitazone from PROactive
were applied for only 5 years. Thereafter, both treatment arms
followed the clinical progression based on event rates from the
placebo arm of PROactive. The discount rate on costs and clinical
beneﬁts were varied in a further sensitivity analysis between 0%
and 6%. To establish the inﬂuence of including quality of life
disutilities not included in the CODE-2 formula (base case),
sensitivity analysis was performed where an “all disutilities”
scenario was considered in which the disutilities were included, in
addition to those previously described from the CODE-2 formula.
Incremental values for discounted quality-adjusted life expectancy
and direct medical costs, as well as incremental cost-effectiveness
ratios were reported from the sensitivity analyses.
Results
Based on data from the PROactive study, the CORE Model
projected that pioglitazone increased life expectancy and quality-
adjusted life expectancy compared with placebo. In the base case,
mean discounted life expectancy increased by 0.237 years with
pioglitazone versus placebo (Table 5). Evaluation of quality-
adjusted life expectancy showed an improvement of 0.166
quality-adjusted life-years associated with pioglitazone versus
placebo (Table 5).
Estimation of long-term complication rates demonstrated
that over the lifetime horizon, pioglitazone was associated with a
reduced number of events per 100 patients versus placebo for
most cardiovascular outcomes (Table 6). Exceptions included
hospitalization for heart failure and peripheral edema. Pioglita-
zone was associated with a reduced risk of stroke, MI, ACS, and
CABG compared with placebo over patient lifetimes; however,
the cumulative number of leg revascularization and amputation
procedures was higher in the pioglitazone arm.
Table 4 Cost per event or state used in the analysis, expressed in 2005 US dollar ($)
Event cost Follow-up cost Reference(s)
Death (all causes) 0 0 Assumed
CVD death 920 0 [37]
MI (excluding silent MI) 20,060 1,937 [38]
Silent MI 0 0 Assumed
Acute coronary syndrome 25,288 1,937 [38,39]
CABG only 37,071 1,937 [37,38]
PCI only 15,904 1,937 [37,38]
Coronary revascularization (CABG + PCI) 52,975 1,937 [37,38]
Stroke 46,420 15,492 [38]
Leg amputation (major, above ankle) 35,043 1,260 [38]
Bypass surgery/revascularization of leg 23,577 2,104 [40]
Transient ischemic attack 4,472 164 [38]
Retinal photocoagulation 971 87 [38]
Hospitalization for CHF 6,874 0 [37]
Peripheral edema 0 0 Assumed to be zero, as patients were
already receiving diuretics in PROactive,
to avoid double counting.
Peripheral vascular disease, onset 4631 0 [41]
Hemodialysis 44,901 44,901 [38]
Peritoneal dialysis 44,901 44,901 [38]
Kidney transplant 44,901 44,901 [38]
Cataract extraction 2,612 0 [38,41]
Neuropathy, onset 401 0 [38]
Uninfected ulcer 1,741 0 [42]
Infected ulcer 3,147 0 [42]
Gangrene 6,139 0 [42]
Major hypoglycemic event 269 0 [38]
Ketoacidosis 13,146 0 [38]
CABG, coronary artery bypass grafting; CHF, congestive heart failure; CVD, cardiovascular disease; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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Over patient lifetimes, the pioglitazone treatment regimen
from PROactive was associated with higher direct medical costs
compared with the placebo regimen (Table 7). Although treat-
ment and management costs with pioglitazone were approxi-
mately $13,569 higher than for placebo over patient lifetimes,
this additional cost was substantially offset by the reduced cost of
diabetes-related complications. Therefore, over patient lifetimes,
total direct medical costs were approximately $7305 more on
pioglitazone than on the placebo regimen. A breakdown of com-
plication costs demonstrated that the main cost savings with
pioglitazone treatment were due to a reduced incidence of stroke
(saving $6117 per patient) and coronary revascularization (coro-
nary artery bypass grafting and percutaneous coronary interven-
tion), saving $1939 per patient (Fig. 1). In contrast, the costs
associated with bypass surgery/revascularization of the leg were
more expensive in the pioglitazone arm than in the placebo arm
(+$2092 per patient), as was hospitalization for heart failure
(+$1045 per patient).
The incremental cost-effectiveness ratios for pioglitazone
versus placebo were $30,792 per life-year gained, and, taking
quality of life into account, $44,105 per quality-adjusted life-
year gained (Table 7). The cost-effectiveness plane indicated that
the majority of points were in the upper right quadrant of the
plane, implying increased effectiveness and increased costs asso-
ciated with pioglitazone versus placebo. The cost-effectiveness
acceptability curve (Fig. 2), demonstrated that at a willingness to
pay of $50,000 per quality-adjusted life-year there was a 55%
likelihood that pioglitazone would be cost effective [31,32].
Sensitivity Analyses
Sensitivity analysis demonstrated that the results were most sen-
sitive to variation in the time horizon and assumptions on the
duration of the beneﬁts of pioglitazone treatment seen in the
trial. Shorter time horizons meant that the development of many
long-term complications were not captured in the analysis. For
example, reduced rates of nephropathy and retinopathy compli-
cations, associated with improved HbA1c levels in patients on
pioglitazone, were not observed at 5- and 10-year time horizons.
When no discounting was applied to the long-term outcomes,
mean life expectancy with pioglitazone was 0.406 years longer
than with placebo. Limiting the duration of pioglitazone effect to
5 years resulted in patients experiencing complications at the
same frequency in both arms of the model over subsequent years
of the simulation, but still accumulating pioglitazone drug acqui-
sition costs in the active treatment arm, which led to a relatively
high incremental cost-effectiveness ratio of $710,455 per quality-
adjusted life gained.
Inclusion of disutilities in the analysis for all macrovascular
events led to a smaller improvement in quality-adjusted life
expectancy with pioglitazone compared with the base case analy-
sis. This increased the incremental cost-effectiveness ratio to
approximately $58,921 per quality-adjusted life-year gained.
Sensitivity analysis where both treatment regimens had an iden-
tical effect on HbA1c, indicated that most of clinical beneﬁt
associated with pioglitazone, in terms of quality-adjusted life
expectancy, was driven by an improved cardiovascular risk
proﬁle rather than reduced HbA1c (incremental beneﬁt 0.178
QALYs versus placebo, base case value 0.180 QALYs). Incremen-
tal costs were also comparable to the base case analysis, leading
to an incremental cost-effectiveness ratio of approximately
$42,258 per QALY gained for pioglitazone versus placebo.
Discussion
PROactive was the ﬁrst clinical trial to demonstrate the potential
for pioglitazone to reduce the incidence of cardiovascular events
in patients with type 2 diabetes and evidence of macrovascular
disease when added to existing therapy [13,14]. The ﬁndings of
this long-term analysis of the cost-effectiveness of pioglitazone
Table 5 Base-case life expectancy and quality-adjusted life expectancy
Outcome Pioglitazone Placebo Difference (PIO–PLA)
Discounted life expectancy (life-years) 12.001 (0.185) 11.764 (0.181) +0.237
QALYs 8.918 (0.133) 8.752 (0.131) +0.166
Undiscounted life expectancy (years) 16.392 (0.302) 15.986 (0.293) +0.406
Values shown are means (SD).
PIO, pioglitazon; PLA, placebo; QALY, quality-adjusted life expectancy.
Table 6 Cumulative complications per 100 patients
Complication
Cumulative events per 100 patients
Pioglitazone Placebo
Difference
(PIO–PLA)
Acute coronary syndrome 24.9 31.0 -6.1
(1.9) (1.9)
Percutaneous coronary
intervention
56.7 60.5 -3.8
(2.9) (2.9)
Coronary artery bypass
graft surgery
27.2 31.6 -4.4
(2.0) (1.8)
Bypass surgery/revascularization
of the leg
37.4 29.2 8.2
(2.3) (1.7)
Hospitalization for CHF 73.9 50.9 23.0
(3.3) (2.4)
Perlpheral edema 158.4 101.3 57.1
(4.9) (3.3)
Myocardial infarction 43.3 51.4 -7.9
(2.4) (2.7)
Transient ischemic attack 22.5 25.0 -2.5
(1.9) (1.7)
Stroke 58.3 69.1 -10.8
(3.2) (3.2)
Photocoagulation 61.8 60.1 1.7
(2.7) (2.7)
Severe vision loss 7.4 7.0 0.4
(0.9) (0.8)
Microalbuminuria 28.1 28.0 0.1
(1.5) (1.4)
Gross proteinuria 17.6 17.3 0.3
(1.2) (1.2)
End-stage renal disease 6.9 6.7 0.2
(0.8) (0.8)
Neuropathy 42.2 41.7 0.5
(1.6) (1.6)
Peripheral vascular disease 23.2 21.8 1.4
(1.4) (1.3)
First foot ulcer 37.0 36.0 1.0
(1.5) (1.5)
Above-ankle amputation 8.9 8.8 0.1
(1.1) (0.9)
Cataract 11.1 11.8 -0.7
(1.0) (1.0)
Values shown are means with standard deviation in parentheses.
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from PROactive in the United States indicate that the addition of
pioglitazone would be associated with an incremental cost-
effectiveness ratio of approximately $44,105 per quality-adjusted
life-year gained, over the lifetime horizon, compared with
placebo. In the base-case analysis, treatment with pioglitazone
was associated with improvements in life expectancy of 0.237
years and quality-adjusted life expectancy of 0.166 QALYs, and
slightly higher direct medical costs ($7305) over the lifetime
horizon. Acceptability curve analysis indicated that there would
be a 55% probability that pioglitazone would be cost-effective at
a willingness to pay threshold of $50,000 per quality-adjusted
life-year gained, compared with placebo.
The CORE Diabetes Model was used to estimate the long-
term cost-effectiveness of pioglitazone versus placebo from PRO-
active by projecting short-term clinical and resource use data
over the lifetime horizon. New submodels were designed to
incorporate primary end point data from PROactive and repre-
sented disease- and procedure-related health states. To facilitate
the modeling process beyond the duration of the PROactive
study, some assumptions were necessary regarding future event
risks, intervention effects, and annual costs. After year 4 in the
model, data from sources other than PROactive were used to
calculate age-related relative risk adjustments for the new sub-
models [21,23,24]. Furthermore, it was assumed that in the ﬁrst
3 years, intervention effects of pioglitazone and placebo would be
based on observations from PROactive, thereafter following the
long-term pattern observed in the UKPDS [4,13,14]. In addition,
the costs associated with medication were based on resource use
data from PROactive for the ﬁrst 3 years, and then it was
assumed that year 3 treatment costs would apply for all subse-
quent years.
Sensitivity analyses were performed to evaluate the impact of
variation in key parameters in the base case outcomes. This
included a shorter time horizon, assuming the change in baseline
HbA1c was equal for pioglitazone and placebo, removing age-
related risk adjustments, shortening the duration of treatment
effect of pioglitazone, varying the discount rate on clinical and
cost outcomes, and applying alternative health state disutilities.
The results were most sensitive to variation in the time horizon
and the duration of pioglitazone effect. Over a 5-year time
horizon, fewer long-term complications were captured so the
long-term clinical beneﬁts of pioglitazone were not observed. A
shorter duration of pioglitazone treatment effect meant fewer
long-term complications being avoided with pioglitazone versus
placebo. The incremental cost-effectiveness ratio for pioglitazone
versus placebo increased to $831,601 and $710,455 per quality-
adjusted life-year gained for shorter time horizon and a shorter
treatment effect, respectively.
This analysis estimated quality-adjusted life expectancy con-
servatively in the base case, using only data from CODE-2, which
did not capture changes in quality of life associated with several
macrovascular end points [18]. It is noteworthy that this meth-
odology may have underestimated the improvements in quality-
adjusted life expectancy, as the formula did not capture some of
the beneﬁts of pioglitazone treatment, including reduced rates of
myocardial infarction, acute coronary syndrome, percutaneous
coronary intervention, and coronary artery bypass graft surgery.
The corollary is that certain disadvantages associated with piogli-
tazone treatment were, similarly, not captured, such as peripheral
edema, hospitalization for heart failure, and revascularization of
the leg. Sensitivity analysis, including disutilities to include these
end points, produced an incremental cost-effectiveness ratio that
was higher than base case ($58,921 per quality-adjusted life-year
gained).
The primary end point of PROactive was a composite of both
disease- and procedure-related events, while its principal second-
ary end point included disease states only [13,14]. Pioglitazone
was associated with a nonsigniﬁcant reduction for the primary
end point and a signiﬁcant reduction for the principal secondary
end point. The conclusions of PROactive have focused on the
principal secondary end point, and the rationale for this
approach has been the subject of some discussion [33–36]. The
aim of this present health economic analysis was not to contrib-
ute to this discussion, but to take all the available outcomes data
from PROactive and project the long-term health and economic
outcomes using a published and validated diabetes model that
derives transition rates and risk adjustments from epidemiologi-
cal studies, including the UKPDS, Wisconsin Epidemiological
Study of Diabetic Retinopathy (WESDR), and Framingham.
The base case mean price per day of therapy (DOT) for
beta-blockers was $8.71 and was based on a weighted average
across the beta-blocker class of therapy. We performed one ﬁnal
sensitivity analysis by lowering the price of beta-blocker therapy
to $4.50/DOT to determine what kind of incremental cost-
effectiveness ratio (ICER) change would result from this reduc-
Table 7 Summary of lifetime economic outcomes
Cost (per patient) Pioglitazone (PIO) Placebo (PLA) Difference (PIO–PLA)
Total direct costs ($) 272,694 (6,795) 265,390 (6,617) 7,305
Treatment and management costs ($) 79,743 66,174 13,569
Complication costs ($) 192,953 199,216 -6,263
ICER based on life expectancy $30,792 per life-year gained
ICER based on quality-adjusted life expectancy $44,105 per QALY gained
Values shown are means (SD). Incremental values are given as the pioglitazone value minus the placebo value.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life expectancy.
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Figure 2 Cost-effectiveness acceptability curve: pioglitazone versus placebo.
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tion in beta-blocker therapy price. The ICER changed from
$44,105 per QALY gained in the base case to $44,708 per QALY
gained, with the lower price for beta-blockers. Basically, there
were more patients in the placebo arm taking beta-blockers. As a
result, lowering the beta-blocker price beneﬁts the placebo arm
slightly over the pioglitazone arm. The result was a marginal
increase in incremental costs and a slightly higher ICER, but not
any dramatic differences.
The PROactive study did not demonstrate a statistically sig-
niﬁcant increased risk of bone fractures with pioglitazone use
compared with placebo, and was therefore not included in this
analysis.
Conclusions
The addition of pioglitazone to existing therapy in patients with
type 2 diabetes and pre-existing macrovascular disease, based on
data from the PROactive study, was projected to be cost-effective
over the lifetime horizon compared with placebo, with an incre-
mental cost-effectiveness ratio of $44,105 per quality-adjusted
life-year gained. At a willingness to pay of $50,000 per quality-
adjusted life-year gained in the United States, there was a 55%
likelihood that pioglitazone would be considered cost-effective.
This study was supported by an unrestricted grant from Takeda Global
Research and Development, Inc., Deerﬁeld, IL, USA.
Source of ﬁnancial support: This study was supported by an unrestricted
grant from Takeda Global Research and Development, Inc, Deerﬁeld, IL,
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